Abstract
Osteocytes in vivo present a unique pattern of gene expression necessary for bone remodeling and mineral metabolism. Genes expressed in osteocytes such as Sost and fibroblast growth factor 23 (FGF23) are essential for load-driven bone formation and regulation of phosphate in the serum, respectively. However, their expression levels in standard cell cultures are significantly low and the mechanism of their transcriptional regulation is hardly examined. Since osteocytes reside in hydroxyapatite (HA)-surrounded lacunae, in this in vitro study we addressed a question whether they would exhibit mRNA expression profiles close to in vivo in the presence of HA. Our hypothesis was that HA would provide a three-dimensional (3D) growth environment important for the regulation of many of the osteocyte characteristic genes. To test this hypothesis, we grew MLO-A5 cells in a 3D collagen matrix with and without HA deposition and conducted a genome-wide expression analysis. The results revealed that deposition of HA markedly elevated the mRNA levels of Sost, dentin matrix protein 1 (DMP1), and FGF23. The microarray derived data indicated potential involvements of Wnt and PI3K signaling. Protein and mRNA expression analysis using pharmacological inhibitors such as LY294002 and pertussis toxin showed that HA-driven gene regulation was in part mediated by Akt in a PI3K pathway and G-protein linked receptors. In summary, we demonstrated herein that HA provided a growth environment that enabled osteocytes to stimulate their characteristic genes such as Sost, DMP1, and FGF23.
Similar content being viewed by others
References
Aarden, E. M., E. H. Burger, and P. J. Mijwede. Function of osteocytes in bone. J. Cell Biochem. 55:287–299, 1994.
Bonewald, L. F. Osteocytes as dynamic multifunctional cells. Ann. N.Y. Acad. Sci. 1116:281–290, 2007.
Boukhechba, F., T. Balaguer, J. F. Michiels, K. Ackermann, D. Quincey, J. M. Bouler, W. Pyerin, G. F. Carle, and N. Rochet. Human primary osteocyte differentiation in a 3D culture system. J. Bone Miner. Res. 24:1927–1935, 2009.
Cadigan, K. M., and R. Nusse. Wnt signaling: a common theme is animal development. Genes Develop. 11:3286–3305, 1997.
Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 296:1655–1657, 2002.
Feng, J. Q., L. M. Ward, S. Liu, Y. Lu, Y. Xie, B. Yuan, X. Yu, F. Rauch, S. I. Davis, S. Zhang, H. Rios, M. K. Drezner, L. D. Quarles, L. F. Bonewald, and K. E. White. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat. Genet. 38:1310–1315, 2006.
Franke, T. F., C. P. Hornik, L. Segev, G. A. Shostak, and C. Sugimoto. PI3K/Akt and apoptosis: size matters. Oncogene 22:8983–8998, 2003.
Fujita, T., Y. Axzuma, R. Fukuyama, Y. Hattori, C. Yoshida, M. Koida, K. Ogita, and T. Komori. Runx2 induces osteoblast and chondrocyte differentiation and enhances their migration by coupling with PI3K-Akt signaling. J. Cell Biol. 166:85–95, 2004.
Kato, Y., A. Boskey, L. Spevak, M. Dallas, M. Hori, and L. F. Bonewald. Establishment of an osteoid preosteocyte-like cell MLO-A5 that spontaneously mineralizes in culture. J. Bone Miner. Res. 16:1622–1633, 2001.
Kost, C., W. Herzer, P. Li, and E. Jackson. Pertussis toxin-sensitive G-proteins and regulation of blood pressure in the spontaneously hypertensive rat. Clin. Exp. Pharmacol. Physiol. 26:449–455, 1999.
Krishnan, V., H. U. Bryant, and O. A. MacDougald. Regulation of bone mass by Wnt signaling. J. Clin. Invest. 116:1202–1209, 2006.
Ling, Y., H. F. Rios, E. R. Myers, Y. Lu, J. Q. Feng, and A. L. Boskey. DMP1 depletion decreases bone mineralization in vivo: an FTIR imaging analysis. J. Bone Miner. Res. 20:2169–2177, 2005.
Liu, S., A. Gupta, and L. D. Quarles. Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr. Opin. Nephrol. Hypertens. 16:329–335, 2007.
Martin, A., S. Liu, V. David, H. Li, A. Karydis, J. Q. Feng, and L. D. Quarles. Bone proteins PHEX and DMP1 regulate fibroblastic growth factor Fgf23 expression in osteocytes through a common pathway involving FGF receptor (FGFR) signaling. FASEB J. 25:2551–2562, 2011.
Nampei, A., J. Hashimoto, K. Hayashida, H. Tsuboi, K. Shi, I. Tsuji, H. Miyashita, T. Yamada, N. Matsukawa, M. Matsumoto, S. Morimoto, T. Ogihara, T. Ochi, and H. Yoshikawa. Matrix extracellular phosphoglycoprotein (MEPE) is highly expressed in osteocytes in human bone. J. Bone Miner. Metab. 22:176–184, 2004.
Noble, B. S., and J. Reeve. Osteocyte function, osteocyte death and bone fracture resistance. Mol. Cell Endocrinol. 159:7–13, 2000.
Papanicolaou, S. E., R. J. Phipps, D. P. Fyhrie, and D. C. Genetos. Modulataion of sclerostin expression by mechanical loading and bone morphogenetic proteins in osteogenic cells. Biorheology 46:389–399, 2009.
Poole, K. E. S., R. L. Bezooijen, N. Loveridge, H. Hamersma, S. E. Papapoulos, C. W. Lowik, and J. Reeve. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19:1842–1844, 2005.
Raheja, L. F., D. C. Genetos, and C. E. Yellowley. Hypoxic osteocytes recruit human MSCs through an OPN/CD44-mediated pathway. Biochem. Biophys. Res. Commun. 366:1061–1066, 2008.
Robinson, J. A., M. Chatterjee-Kishore, P. J. Yaworsky, D. M. Cullen, W. Zhao, C. Li, Y. Kharode, L. Sauter, P. Babij, E. L. Brown, A. A. Hill, M. P. Akhter, M. L. Johnson, R. R. Recker, B. S. Komm, and F. J. Bex. Wnt/beta-catenin signaling is a normal physiological response to mechanical loading in bone. J. Biol. Chem. 20:31720–31728, 2006.
Robling, A. G., P. J. Niziolek, L. A. Baldridge, K. W. Condon, M. R. Allen, I. Alam, S. M. Mantila, J. Gluhak-Heinrich, T. M. Bellido, S. E. Harris, and C. H. Turner. Mechanical stimulation of bone in vivo reduces osteocyte expression of sost/sclerostin. J. Biol. Chem. 283:5866–5875, 2008.
Sawakami, K., A. G. Robling, M. Ai, N. D. Pitner, D. Liu, S. J. Warden, J. Li, P. Maye, D. W. Rowe, R. L. Duncan, M. L. Warman, and C. H. Turner. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem. 281:2369–2711, 2006.
Schmidmaier, G., B. Wildemann, J. Heeger, T. Gabelein, A. Flyvbjerg, H. J. Bail, and M. Raschke. Improvement of fracture healing by systemic administration of growth hormone and local application of insulin-like growth factor-1 and transforming growth factor-β1. Bone 31:165–172, 2002.
Schneider, P., M. Meier, R. Wepf, and R. Muller. Towards quantitative 3D imaging of the osteocyte lacuna-canalicular network. Bone 47:848–858, 2010.
Shimada, T., H. Hasegawa, Y. Yamazaki, T. Muto, R. Hino, Y. Takeuchi, T. Fujita, K. Nakahara, S. Fukumoto, and T. Yamashita. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19:429–435, 2003.
Tanaka, S. M., H. B. Sun, R. K. Roeder, D. B. Burr, C. H. Turner, and H. Yokota. Osteoblast responses to load-induced fluid flow for one hour in a three-dimensional porous matrix. Calcified Tissue Int. 76:261–271, 2005.
Ubaidus, S., M. Li, S. Sultana, P. H. L. De Freitas, K. Oda, T. Maeda, R. Takagi, and N. Amizuka. FGF23 is mainly synthesized by osteocytes in the regularly distributed osteocytic lacunar canalicular system established after physiological bone remodeling. J. Electron Micros. 58:381–392, 2009.
Vlahos, C. J., W. F. Matter, K. Y. Hui, and R. F. Brown. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269:5241–5248, 1994.
Warden, S. J., A. G. Roblong, M. S. Sanderrs, M. M. Bliziotes, and C. H. Turner. Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. Endocrinology 146:685–693, 2005.
White, K. E., T. L. Larsson, and M. J. Econs. The role of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related proteins-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. Endocr. Rev. 27:221–241, 2006.
Xia, X., N. Batra, Q. Shi, L. F. Bonewald, E. Sprague, and J. X. Jiang. Prostaglandin promotion of osteocyte gap junction function through transcriptional regulation of connexin 43 by glycogen synthase kinase 3/β-catenin signaling. Mol. Cell Biol. 30:206–219, 2010.
Yu, X., and K. E. White. FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev. 16:221–232, 2005.
Zhang, P., C. H. Turner, and H. Yokota. Joint loading-driven bone formation and signaling pathways predicted from genome-wide expression profiles. Bone 44:989–998, 2009.
Acknowledgments
We appreciate L.F. Bonewald for providing MLO-A5 osteocyte-like cells and M. Tawfik for technical support. This study was in part supported by NIH R01 AR052144.
Author information
Authors and Affiliations
Corresponding author
Additional information
Associate Editor Christopher Rae Jacobs oversaw the review of this article.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Hamamura, K., Zhao, L., Jiang, C. et al. Hydroxyapatite Modulates mRNA Expression Profiles in Cultured Osteocytes. Cel. Mol. Bioeng. 5, 217–226 (2012). https://doi.org/10.1007/s12195-012-0228-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12195-012-0228-9